+Compare
BIIB
Stock ticker: NASDAQ
AS OF
Loading...
Price
Loading...
Change
Loading...
Capitalization
37.5B

BIIB Biogen Forecast, Technical & Fundamental Analysis

a manufacturer of therapies for people living with neurological, autoimmune and hematologic disorders

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), Merck & Co (NYSE:MRK), ABBVIE (NYSE:ABBV), AstraZeneca PLC (NASDAQ:AZN), Pfizer (NYSE:PFE), Amgen (NASDAQ:AMGN), Bristol-Myers Squibb Co (NYSE:BMY), Gilead Sciences (NASDAQ:GILD), Biogen (NASDAQ:BIIB).

Industry description

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

Market Cap

The average market capitalization across the Pharmaceuticals: Major Industry is 80.58B. The market cap for tickers in the group ranges from 72.83K to 522.24B. LLY holds the highest valuation in this group at 522.24B. The lowest valued company is CRXTQ at 72.83K.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Major Industry was -2%. For the same Industry, the average monthly price growth was -3%, and the average quarterly price growth was -0%. MIRA experienced the highest price growth at 39%, while SCLX experienced the biggest fall at -30%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Major Industry was -52%. For the same stocks of the Industry, the average monthly volume growth was -60% and the average quarterly volume growth was 4%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 28
P/E Growth Rating: 58
Price Growth Rating: 57
SMR Rating: 57
Profit Risk Rating: 67
Seasonality Score: -21 (-100 ... +100)
View a ticker or compare two or three
A.I. Advisor
published Earnings

BIIB is expected to report earnings to $3.99 per share on October 24

Biogen BIIB Stock Earnings Reports
Q3'23
Est.
$3.99
Q2'23
Beat
by $0.24
Q1'23
Beat
by $0.12
Q4'22
Beat
by $0.57
Q3'22
Beat
by $0.64
The last earnings report on July 25 showed earnings per share of $4.02, beating the estimate of $3.78. With 799.87K shares outstanding, the current market capitalization sits at 37.50B.
A.I. Advisor
published General Information

General Information

a manufacturer of therapies for people living with neurological, autoimmune and hematologic disorders

Industry PharmaceuticalsMajor

Profile
Fundamentals
Details
Industry
Biotechnology
Address
225 Binney Street
Phone
+1 617 679-2000
Employees
8725
Web
https://www.biogen.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
GBPIX10.56N/A
N/A
Meeder Global Allocation Institutional
KLCKX19.32N/A
N/A
Federated Hermes Kaufmann Large Cap R
SBLYX57.58-0.01
-0.02%
ClearBridge Large Cap Growth I
NFALX22.78-0.02
-0.09%
Neuberger Berman Focus I
LCMGX14.73-0.11
-0.74%
Lord Abbett Micro Cap Growth C

BIIB and

Correlation & Price change

A.I.dvisor indicates that over the last year, BIIB has been loosely correlated with AZN. These tickers have moved in lockstep 34% of the time. This A.I.-generated data suggests there is some statistical probability that if BIIB jumps, then AZN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BIIB
1D Price
Change %
BIIB100%
-0.48%
AZN - BIIB
34%
Loosely correlated
+1.21%
JNJ - BIIB
32%
Poorly correlated
-0.72%
MRK - BIIB
29%
Poorly correlated
-0.37%
PFE - BIIB
29%
Poorly correlated
-0.49%
ABBV - BIIB
27%
Poorly correlated
-0.45%
More

Groups containing BIIB

Correlation & Price change

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BIIB
1D Price
Change %
BIIB100%
-0.48%
autoimmune
(undefined stocks)
99%
Closely correlated
-3.30%
neurological
(undefined stocks)
76%
Closely correlated
+0.07%
therapy
(undefined stocks)
67%
Closely correlated
-0.81%
challenging disorders
(undefined stocks)
64%
Loosely correlated
-1.94%
Pharmaceuticals: Major
(undefined stocks)
40%
Loosely correlated
-0.13%
More